GlobalData on MSN1d
Teva’s long-lasting schizophrenia injectable shines in Phase IIIData presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...
Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...
Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...
Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday.
In late September, the FDA approved xanomeline and trospium chloride (Cobenfy) for schizophrenia in adults, the first new ...
Bristol Myers Squibb reported strong third-quarter financial results, notching an 18% jump in its growth portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback